Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company dedicated to the discovery and development of novel treatments for viral diseases and cancer. Ambrilia’s broad pipeline includes proprietary mid to early-stage products and two new formulations of existing drugs.
Ambrilia’s Octreotide, is a prolonged-release therapeutic alternative to Novartis’ Sandostatin®LAR, used for the treatment of a rare disease called acromegaly caused by a tumor of the pituitary gland, and for certain digestive tumors. Goserelin, is a potential first-to-market prolonged release therapeutic alternative to Astra Zeneca’s Zoladex® used primarily for the treatment of hormone-sensitive prostate cancer. Proprietary mid to early-stage products include: PPL-100, a promising protease inhibitor for the treatment of HIV/AIDS and for which Ambrilia granted Merck & Co. the exclusive worldwide rights; PCK3145, a therapeutic anti-cancer peptide with signal transduction mediated effects on tumor metastasis for the treatment of hormone-resistant prostate cancer; a tumor and tumor vasculature targeting (TVT) technology platform for solid tumors, an Integrase Inhibitor Program for the treatment of HIV/AIDS and several other early-stage anti-virals and immunomodulators.
Ambrilia’s diagnostic products include PSP94 (Prostate Secretory Protein of 94 amino acids) a novel biomarker assay for the diagnostic and prognostic of prostate cancer.
Ambrilia’s head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. Ambrilia’s common shares are traded on the Toronto Stock Exchange under the ticker symbol AMB.